
AstraZeneca has unveiled a tie-up with China’s CSPC Pharmaceutical Group to ramp up development of experimental weight loss and diabetes drugs in a deal worth 18.5 billion US dollars (£13.4 billion) as it looks to tap further into the booming sector.
Under the deal, the FTSE 100 pharmaceutical giant will have access to the exclusive global rights, outside China, to CSPC’s once-a-month dose technology portfolio for weight management to offer more convenient solutions to daily injections.